Your browser doesn't support javascript.
loading
Establishing a natural history of X-linked dystonia parkinsonism.
Acuna, Patrick; Supnet-Wells, Melanie Leigh; Spencer, Neil A; de Guzman, Jan Kristoper; Russo, Massimiliano; Hunt, Ann; Stephen, Christopher; Go, Criscely; Carr, Samuel; Ganza, Niecy Grace; Lagarde, John Benedict; Begalan, Shin; Multhaupt-Buell, Trisha; Aldykiewicz, Gabrielle; Paul, Lisa; Ozelius, Laurie; Bragg, D Cristopher; Perry, Bridget; Green, Jordan R; Miller, Jeffrey W; Sharma, Nutan.
Afiliação
  • Acuna P; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Supnet-Wells ML; The Collaborative Center for X-linked Dystonia-Parkinsonism, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Spencer NA; Sunshine Care Foundation, The Health Centrum, Roxas City, Capiz 5800Philippines.
  • de Guzman JK; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Russo M; The Collaborative Center for X-linked Dystonia-Parkinsonism, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Hunt A; Department of Statistics, University of Connecticut, Storrs, CT 06269, USA.
  • Stephen C; Department of Neurology, Jose Reyes Memorial Medical Center, Manila, Metro Manila, 1012Philippines.
  • Go C; Sunshine Care Foundation, The Health Centrum, Roxas City, Capiz 5800Philippines.
  • Carr S; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Ganza NG; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Lagarde JB; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Begalan S; Department of Neurology, Jose Reyes Memorial Medical Center, Manila, Metro Manila, 1012Philippines.
  • Multhaupt-Buell T; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Aldykiewicz G; Sunshine Care Foundation, The Health Centrum, Roxas City, Capiz 5800Philippines.
  • Paul L; Sunshine Care Foundation, The Health Centrum, Roxas City, Capiz 5800Philippines.
  • Ozelius L; Sunshine Care Foundation, The Health Centrum, Roxas City, Capiz 5800Philippines.
  • Bragg DC; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Perry B; The Collaborative Center for X-linked Dystonia-Parkinsonism, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Green JR; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Miller JW; The Collaborative Center for X-linked Dystonia-Parkinsonism, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Sharma N; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Brain Commun ; 5(3): fcad106, 2023.
Article em En | MEDLINE | ID: mdl-37265597
X-linked dystonia parkinsonism is a neurodegenerative movement disorder that affects men whose mothers originate from the island of Panay, Philippines. Current evidence indicates that the most likely cause is an expansion in the TAF1 gene that may be amenable to treatment. To prepare for clinical trials of therapeutic candidates for X-linked dystonia parkinsonism, we focused on the identification of quantitative phenotypic measures that are most strongly associated with disease progression. Our main objective is to establish a comprehensive, quantitative assessment of movement dysfunction and bulbar motor impairments that are sensitive and specific to disease progression in persons with X-linked dystonia parkinsonism. These measures will set the stage for future treatment trials. We enrolled patients with X-linked dystonia parkinsonism and performed a comprehensive oromotor, speech and neurological assessment. Measurements included patient-reported questionnaires regarding daily living activities and both neurologist-rated movement scales and objective quantitative measures of bulbar function and nutritional status. Patients were followed for 18 months from the date of enrollment and evaluated every 6 months during that period. We analysed a total of 87 men: 29 were gene-positive and had symptoms at enrollment, seven were gene-positive and had no symptoms at enrollment and 51 were gene-negative. We identified measures that displayed a significant change over the study. We used principal variables analysis to identify a minimal battery of 21 measures that explains 67.3% of the variance over the course of the study. These measures included patient-reported, clinician-rated and objective quantitative outcomes that may serve as endpoints in future clinical trials.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos